Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
An important function of hepatocytes is the biotransformation and elimination of various drugs, many of which are organic cations and are taken up by organic cation transporters (OCTs) of the solute carrier family 22 (SLC22). Because interindividual variability of OCT expression may affect response to cationic drugs such as metformin, we systematically investigated genetic and nongenetic factors of OCT1/SLC22A1 and OCT3/SLC22A3 expression in human liver. OCT1 and OCT3 expression (messenger RNA [mRNA], protein) was analyzed in liver tissue samples from 150 Caucasian subjects. Hepatic OCTs were localized by way of immunofluorescence microscopy. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and genome-wide single-nucleotide polymorphism microarray technology served to genotype 92 variants in the SLC22A1-A3/OCT1-3 gene cluster. Transport of metformin by recombinant human OCT1 and OCT3 was compared using transfected cells. OCT1 mRNA and protein expression varied 113- and 83-fold, respectively; OCT3 mRNA expression varied 27-fold. OCT1 transcript levels were on average 15-fold higher compared with OCT3. We localized the OCT3 protein to the basolateral hepatocyte membrane and identified metformin as an OCT3 substrate. OCT1 and OCT3 expression are independent of age and sex but were significantly reduced in liver donors diagnosed as cholestatic (P < or = 0.01). Several haplotypes for OCT1 and OCT3 were identified. Multivariate analysis adjusted for multiple testing showed that only the OCT1-Arg61Cys variant (rs12208357) strongly correlated with decreased OCT1 protein expression (P < 0.0001), and four variants in OCT3 (rs2292334, rs2048327, rs1810126, rs3088442) were associated with reduced OCT3 mRNA levels (P = 0.03).


CONCLUSIONS
We identified cholestasis and genetic variants as critical determinants for considerable interindividual variability of hepatic OCT1 and OCT3 expression. This indicates consequences for hepatic elimination of and response to OCT substrates such as metformin.
Nies
Anne T
AT
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.
Koepsell
Hermann
H
Winter
Stefan
S
Burk
Oliver
O
Klein
Kathrin
K
Kerb
Reinhold
R
Zanger
Ulrich M
UM
Keppler
Dietrich
D
Schwab
Matthias
M
Schaeffeler
Elke
E
D001692:Biological Transport / Q000502:physiology; D002779:Cholestasis / Q000378:metabolism* / Q000473:pathology; D005787:Gene Frequency / Q000235:genetics; D005947:Glucose / Q000378:metabolism; D006239:Haplotypes / Q000235:genetics; D022781:Hepatocytes / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000493:pharmacokinetics; D008099:Liver / Q000378:metabolism* / Q000473:pathology; D008687:Metformin / Q000493:pharmacokinetics; D015999:Multivariate Analysis; D050811:Octamer Transcription Factor-1 / Q000235:genetics* / Q000378:metabolism*; D027701:Organic Cation Transport Proteins / Q000235:genetics* / Q000378:metabolism*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D044465:White People / Q000235:genetics; D000099254:Organic Cation Transporter 3
D005947:Glucose; D007004:Hypoglycemic Agents; D008687:Metformin; D050811:Octamer Transcription Factor-1; D027701:Organic Cation Transport Proteins; D012333:RNA, Messenger; D000099254:Organic Cation Transporter 3; C494165:POU2F1 protein, human